Skip to main content

Table 2 Clinical assessment result changes from baseline to week 120 in the rituximab and DMARD treatment groups

From: Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study

  BASELINE Week 12 Week 24 Week 48 Week 72 Week 96 Week 120
  DMARDs RTX DMARDs RTX DMARDs RTX DMARDs RTX DMARDs RTX DMARDs RTX DMARDs RTX
Global disease activity VAS (mm) 88.7 ± 3.3 88.7 ± 3.3 77 ± 2.2† 72.4 ± 4.0‡ 71 ± 3.2‡ 68.5 ± 4.6‡ 63 ± 3.9* 60.0 ± 4.6* 54 ± 3.5* 51.8 ± 3.0* 50.5 ± 3.7* 47.1 ± 3.5* 52.1 ± 4.8* 45.3 ± 3.9*
Pain VAS (mm) 70.1 ± 9.0 71.1 ± 8.7 59.8 ± 7.8† 55 ± 7.4† 56.7 ± 7.8‡ 53.5 ± 7.5‡ 51.3 ± 7.5* 44.1 ± 8.5* 41 ± 7.6* 36.3 ± 7.9* 40.5 ± 7.5* 33.1 ± 7.0* 39.3 ± 8.3* 29.8 ± 7.8*
Fatigue VAS (mm) 85.1 ± 4.6 83.8 ± 4.1 73 ± 4.5† 63.1 ± 4.3‡ 63.1 ± 4.7‡ 58.7 ± 5.1‡ 60.1 ± 4.4* 56.2 ± 5.5* 52.2 ± 4.0* 47.8 ± 4.7* 50.5 ± 3.8* 42.5 ± 4.1* 51.8 ± 4.5* 41.1 ± 4.2*
Dryness VAS (mm) 71.0 ± 8.3 72 ± 8.5 61.1 ± 8.3 55.3 ± 7.6‡ 58 ± 8.2† 52.2 ± 7.6‡ 56.3 ± 8.4‡ 44.1 ± 8.5* 53.8 ± 11.0* 36.3 ± 7.9* 51.8 ± 10.4* 30.7 ± 8.0* 51.8 ± 11.1* 25.1 ± 7.7*
Physician GA VAS (mm) 89.7 ± 3.0 87.1 ± 2.3 78.6 ± 2.6† 69.1 ± 3.0† 73.1 ± 3.4‡ 65 ± 4.4‡ 65.0 ± 3.9* 56.6 ± 4.3* 56.6 ± 3.8* 50.3 ± 3.0* 54.7 ± 4.5* 45.8 ± 3.3* 56.1 ± 4.9* 44.0 ± 3.7*
Unstimulated salivary flow (ml/minute) 0.08 ± 0.03 0.08 ± 0.04 0.1 ± 0.04 0.2 ± 0.04‡ 0.1 ± 0.04 0.3 ± 0.04‡ 0.1 ± 0.07 0.4 ± 0.02* 0.1 ± 0.06 0.3 ± 0.001* 0.1 ± 0.08 0.4 ± 0.04* 0.1 ± 0.08 0.4 ± 0.04*
Schirmer I test (mm/5 minutes) 3.8 ± 0.6 3.8 ± 0.6 4 ± 0.5 5.5 ± 0.4‡ 4.5 ± 0.7 6.0 ± 0.5† 5.1 ± 0.8 6.3 ± 0.6‡ 5.1 ± 0.7 7.0 ± 0.7* 5.3 ± 0.7† 7.0 ± 0.7* 5.5 ± 0.8‡ 7.3 ± 0.8*
ESSDAI 19.8 ± 3.1 20.3 ± 2.9 17.6 ± 3.2 14.2a ± 2.8 14.2 ± 3.0‡ 9.8 ± 2.0‡ 12.3 ± 2.0* 9.4 ± 1.6‡ 10.2 ± 2.0* 5.7 ± 1.0* 9.7 ± 2.0* 5.7 ± 1.0* 8.8 ± 1.7* 5.2 ± 0.9*
  1. Data presented as mean ± standard error of the mean. DMARD, disease-modifying anti-rheumatic drug; ESSDAI, EULAR Sjögren’s syndrome disease activity index; GA, global assessment; RTX, rituximab; VAS, visual analogic scale. *P <0.001;‡P <0.01; †P <0.05.